Hansa Biopharma, (STO: HNSA), a Sweden-based company involved in enzyme technology for rare immunological conditions, announced on Friday that it has named Matthew Shaulis as its new chief commercial officer and president of the US affiliate, Hansa Biopharma, Inc effective 16 March.

Shaulis has more than 20 years of US and international experience in the pharmaceutical industry. He has served in various senior executive roles, including president, Inflammation and Immunology for the International Developed Markets, president, North America Oncology and senior vice president at Pfizer. He has also served in roles of increasing responsibility in global strategic marketing and sales leadership, strategic customer group management and licensing and acquisition and in product and indication launches across multiple disease areas at Teva, Cephalon, Johnson & Johnson and Schering-Plough.

Soren Tulstrup, president and CEO, Hansa Biopharma said, 'Hansa is fast evolving into a full-fledged, integrated global commercial stage biotechnology company and now is the right time to further strengthen our commercial and in-market leadership as we continue to build a high-performing commercial function and create a US-focused organisation that will help deliver our goal of bringing imlifidase to the US. We are excited to welcome Matthew to Hansa and this underscores our commitment to bringing on board high calibre talent. I would like to thank and congratulate Henk Doude van Troostwijk, who is moving into a new role as vice president, Commercial Excellence, for his many contributions.'